Skip to content

In the BioHarmony Drug Report Database

Loncastuximab tesirine

Zynlonta (loncastuximab tesirine) is an antibody pharmaceutical. Loncastuximab tesirine was first approved as Zynlonta on 2021-04-23. It is used to treat large b-cell lymphoma diffuse in the USA. It is known to target B-lymphocyte antigen CD19.
Trade Name Zynlonta
Common Name Loncastuximab tesirine
Indication large b-cell lymphoma diffuse
Drug Class Monoclonal antibodies: chimeric, tumors as target
Loncastuximab tesirine
Get full access now